054670 — Daehan Nupharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapValue Trap

Annual income statement for Daehan Nupharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	166,586	197,957	204,223	202,187	202,401
Cost of Revenue
Gross Profit	83,969	90,546	93,983	96,880	92,261
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	141,467	161,475	185,413	183,522	190,677
Operating Profit	25,119	36,482	18,809	18,665	11,725
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23,580	34,520	20,683	18,375	14,983
Provision for Income Taxes
Net Income After Taxes	15,694	24,317	12,542	15,468	15,258
Net Income Before Extraordinary Items
Net Income	15,694	24,317	12,542	15,468	15,258
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	15,694	24,317	12,542	15,468	15,258
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,193	1,285	894	1,102	1,101
Dividends per Share